Literature DB >> 26219522

[Obliteration of mastoid cavities: 30 years of experience with recommendations for surgical strategy].

G Schimanski1, E Schimanski.   

Abstract

BACKGROUND: The obliteration of mastoid cavities is an appropriate intervention to sustainably improve patients' quality of life.
MATERIALS AND METHODS: After 30 years, 843 cases of mastoid obliteration were analyzed from the pool of data resulting from 16,000 surgical procedures on the ear. The materials used by the authors included cartilage/bone, Palva flaps, and bone pâté; as well as alloplastic material such as hydroxyapatite (HA) and bioactive glass granules (BAG S53P4) from BonAlive® (BonAlive Biomaterials Ltd., Turku, Finland). Pathological findings included rejection with inflammation, granulation of the auditory canal reconstruction, unclear retraction pockets, as well as shrinkage and cicatricial contraction. The follow-up interval was at least 4 months, with an average of 33 months (standard deviation ± 27.8 months).
RESULTS: Use of HA was discontinued after 18 cases, because rejection and retraction occurred in 33% of patients. The same applied for bone pâté after 33 cases, with a pathological finding in 21%. The Palva flaps (145 cases) showed pathological findings in 21% of cases, primarily in the form of shrinkage (7%) and retractions (10%). Cartilage/bone pieces (516 cases) and BAG S53P4 (133 cases) only showed abnormal postoperative findings in 8% and 3%, respectively. It is recommended to focus particularly on auditory canal and canal entrance expansion during mastoid obliteration surgery. When using the bioactive glass granules, postoperative use of a mini-drain for 1-2 days is beneficial, in order to avoid accumulation of seroma fluid in the mastoid.
CONCLUSION: In our experience, a combination of BAG S53P4 and cartilage as cover is a suitable material for cavity obliteration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26219522     DOI: 10.1007/s00106-015-0028-3

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  30 in total

1.  Mastoidectomy reconstruction: use of aluminum templates to shape hydroxylapatite canal wall implants.

Authors:  B Black
Journal:  Am J Otol       Date:  1991-11

2.  Obliteration of the persistently discharging mastoid cavity using the middle temporal artery flap.

Authors:  Vivian Singh; Marcus Atlas
Journal:  Otolaryngol Head Neck Surg       Date:  2007-09       Impact factor: 3.497

3.  Use of mastoid obliteration techniques in cholesteatoma.

Authors:  Matthew Yung; Alex Bennett
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2013-10       Impact factor: 2.064

4.  Bioactive glass S53P4 in repair of septal perforations and its interactions with the respiratory infection-associated microorganisms Haemophilus influenzae and Streptococcus pneumoniae.

Authors:  P Stoor; E Söderling; R Grénman
Journal:  J Biomed Mater Res       Date:  2001

5.  Musculoperiosteal flap in cavity obliteration. Histopathological study seven years postoperatively.

Authors:  T Palva; A Palva; J Kärjä
Journal:  Arch Otolaryngol       Date:  1972-02

6.  Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience.

Authors:  Matti Peltola; Kalle Aitasalo; Jouko Suonpää; Matti Varpula; Antti Yli-Urpo
Journal:  Head Neck       Date:  2006-09       Impact factor: 3.147

7.  Bioactive glass-ceramics in ear surgery: animal studies and clinical results.

Authors:  R Reck
Journal:  Laryngoscope       Date:  1984-02       Impact factor: 3.325

8.  Bioactive glass S53P4 in mastoid obliteration surgery for chronic otitis media and cerebrospinal fluid leakage.

Authors:  Jussi Sarin; Reidar Grénman; Kalle Aitasalo; Jaakko Pulkkinen
Journal:  Ann Otol Rhinol Laryngol       Date:  2012-09       Impact factor: 1.547

9.  Impact of partial mastoid obliteration on caloric vestibular function in canal wall down mastoidectomy.

Authors:  Dirk Beutner; Victor Helmstaedter; Robert Stumpf; Thomas Beleites; Thomas Zahnert; Jan Christoffer Luers; Karl-Bernd Huttenbrink
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

10.  Toxicology and biocompatibility of bioglasses.

Authors:  J Wilson; G H Pigott; F J Schoen; L L Hench
Journal:  J Biomed Mater Res       Date:  1981-11
View more
  2 in total

1.  Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

Authors:  F L J Cals; H F E van der Toom; R M Metselaar; A van Linge; M P van der Schroeff; R J Pauw
Journal:  J Otol       Date:  2021-10-29

2.  Management of tegmen defects with mastoid and epitympanic obliteration using S53P4 bioactive glass.

Authors:  Françoise Remangeon; Ghizlene Lahlou; Lauranne Alciato; Frederic Tankere; Isabelle Mosnier; Olivier Sterkers; Nadya Pyatigorskaya; Daniele Bernardeschi
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.